Developers of digital therapeutics – defined by the Digital Therapeutics Alliance as “evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease” – have experienced tremendous growth and investor interest during the pandemic.
The need for addressing mental health issues combined with a more relaxed US Food and Drug Administration approach that expands the use of digital health therapeutics for psychiatric disorders for the duration of the pandemic has helped drive this growth with companies such as
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?